[
    {
        "query": "\nSummarize the main idea and key results of each paper using the provided excerpts and metadata. Include:\n1. **Title** (from metadata)\n2. **Abstract** (if available)\n3. **Main idea and hypothesis**: It should clearly states the hypothesis which the paper is written based on it accordingly.\n4. **Summary of Results**: Key findings, conclusions, or implications.\nProvide clear and concise summaries for each paper.\n",
        "response": "Here's a summary of the main idea and key results of each paper, based on the provided excerpts:\n\n\n**1. A dataset of images and morphological profiles of 30,000 small-molecule treatments using the cell painting assay.**\n\n1. **Title:** A dataset of images and morphological profiles of 30,000 small-molecule treatments using the cell painting assay.\n\n2. **Abstract:**  Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To create a large-scale dataset of images and morphological profiles of cells treated with small molecules using the Cell Painting assay.  The underlying hypothesis is that this high-content image-based data will be useful for drug discovery research.\n\n4. **Summary of Results:** The paper describes the creation and release of a dataset containing 30,000 small-molecule treatments using the Cell Painting assay.  The dataset is a resource for future research in drug discovery.\n\n\n**2. A mammalian protein targeted by g1-arresting rapamycin\u2013receptor complex.**\n\n1. **Title:** A mammalian protein targeted by g1-arresting rapamycin\u2013receptor complex.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To identify a mammalian protein that is the target of the rapamycin-receptor complex, which is known to induce G1 cell cycle arrest.  The hypothesis is that such a protein exists and can be identified through experimental means.\n\n4. **Summary of Results:** The authors identified a mammalian protein, FKBP12, as a target of the rapamycin-receptor complex.\n\n\n**3. GuacaMol: Benchmarking models for de novo molecular design.**\n\n1. **Title:** GuacaMol: Benchmarking models for de novo molecular design.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To create and utilize a benchmark (GuacaMol) for evaluating models that design new molecules. The hypothesis is that a standardized benchmark is needed to objectively compare the performance of different de novo molecular design models.\n\n4. **Summary of Results:** The paper presents GuacaMol, a benchmark for evaluating de novo molecular design models. It allows for the objective comparison of different models based on various metrics.\n\n\n**4. High-content phenotypic profiling of drug response signatures across distinct cancer cells.**\n\n1. **Title:** High-content phenotypic profiling of drug response signatures across distinct cancer cells.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To profile drug responses across different cancer cell lines using high-content phenotypic screening. The hypothesis is that different cancer cell lines will exhibit distinct phenotypic responses to drugs, potentially revealing new targets or mechanisms of action.\n\n4. **Summary of Results:** The study used high-content phenotypic profiling to characterize drug response signatures in various cancer cell lines. The results likely showed distinct phenotypic responses, useful in drug discovery.\n\n\n**5. Image-based profiling for drug discovery: due for a machine-learning upgrade?**\n\n1. **Title:** Image-based profiling for drug discovery: due for a machine-learning upgrade?\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To argue that machine learning is needed to improve image-based profiling in drug discovery. The hypothesis is that machine learning techniques can enhance the analysis and interpretation of image-based profiling data, leading to more efficient drug discovery.\n\n4. **Summary of Results:** The authors advocate for the application of machine learning to enhance image-based profiling for drug discovery, highlighting its potential to improve efficiency and effectiveness.\n\n\n**6. JUMP cell painting dataset: morphological impact of 136,000 chemical and genetic perturbations.**\n\n1. **Title:** JUMP cell painting dataset: morphological impact of 136,000 chemical and genetic perturbations.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To create and release a large-scale dataset (JUMP) of cell images showing the morphological effects of chemical and genetic perturbations.  The hypothesis is that this dataset will be valuable for training machine learning models for drug discovery.\n\n4. **Summary of Results:** The paper describes the creation and release of the JUMP dataset, a massive resource containing morphological profiles of cells following various chemical and genetic perturbations.\n\n\n**7. Three million images and morphological profiles of cells treated with matched chemical and genetic perturbations.**\n\n1. **Title:** Three million images and morphological profiles of cells treated with matched chemical and genetic perturbations.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To expand on the JUMP dataset, providing a significantly larger collection of images and morphological profiles.  The hypothesis is that more data will improve the accuracy and utility of machine learning models trained on this data for drug discovery.\n\n4. **Summary of Results:**  The paper details the expansion of the JUMP dataset to include three million images, offering even richer data for machine learning applications in drug discovery.\n\n\n**8. In silico labeling: Predicting fluorescent labels in unlabeled images.**\n\n1. **Title:** In silico labeling: Predicting fluorescent labels in unlabeled images.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To develop a method for computationally predicting fluorescent labels in unlabeled images. The hypothesis is that it's possible to predict the fluorescent labels based on the image content using machine learning.\n\n4. **Summary of Results:** The authors developed a method for *in silico* labeling of images, predicting fluorescent labels based on image features.\n\n\n**9. Scaling vision transformers to 22 billion parameters.**\n\n1. **Title:** Scaling vision transformers to 22 billion parameters.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To investigate the effect of scaling up vision transformers (a type of deep learning model) to extremely large sizes. The hypothesis is that increasing the model size and the amount of training data will improve performance.\n\n4. **Summary of Results:**  The research explored scaling vision transformers to a massive 22 billion parameters, likely demonstrating improved performance with increased scale.\n\n\n**10. Cell-based screening: extracting meaning from complex data.**\n\n1. **Title:** Cell-based screening: extracting meaning from complex data.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To discuss the challenges of analyzing complex data from cell-based screening experiments and suggest methods to extract meaningful information. The hypothesis is that effective data analysis techniques are needed to fully utilize the information from cell-based screening.\n\n4. **Summary of Results:** The paper addresses the complexities of analyzing cell-based screening data and proposes strategies for extracting meaningful insights.\n\n\n**11. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.**\n\n1. **Title:** A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To identify the receptor for the immunosuppressant drug FK506. The hypothesis is that the receptor is a specific type of enzyme, a cis-trans peptidyl-prolyl isomerase.\n\n4. **Summary of Results:** The authors identified the receptor for FK506 as a specific type of peptidyl-prolyl isomerase.\n\n\n**12. Gaussian error linear units (GELUs).**\n\n1. **Title:** Gaussian error linear units (GELUs).\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To introduce a new activation function (GELU) for neural networks. The hypothesis is that GELU will improve the performance of neural networks compared to existing activation functions.\n\n4. **Summary of Results:** The paper introduces GELU, a novel activation function for neural networks, and likely demonstrates its effectiveness.\n\n\n**13. RITA: a study on scaling up generative protein sequence models.**\n\n1. **Title:** RITA: a study on scaling up generative protein sequence models.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To investigate the effects of scaling up generative models for protein sequences.  The hypothesis is that larger models trained on more data will generate more realistic and functional protein sequences.\n\n4. **Summary of Results:** The study likely showed that scaling up generative protein sequence models improves their ability to generate realistic and functional sequences.\n\n\n**14. Scaling laws for single-agent reinforcement learning.**\n\n1. **Title:** Scaling laws for single-agent reinforcement learning.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To investigate scaling laws in single-agent reinforcement learning. The hypothesis is that performance in single-agent reinforcement learning is predictable based on the scale of computation, data, and model parameters.\n\n4. **Summary of Results:**  The research likely identified scaling laws that govern the performance of single-agent reinforcement learning models.\n\n\n**15. High-Content phenotypic profiling in esophageal adenocarcinoma identifies selectively active pharmacological classes of drugs for repurposing and chemical starting points for novel drug discovery.**\n\n1. **Title:** High-Content phenotypic profiling in esophageal adenocarcinoma identifies selectively active pharmacological classes of drugs for repurposing and chemical starting points for novel drug discovery.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To identify potential drug candidates for treating esophageal adenocarcinoma using high-content phenotypic profiling. The hypothesis is that this approach can identify drugs with selective activity against esophageal adenocarcinoma cells.\n\n4. **Summary of Results:** The study likely identified novel drug candidates or chemical starting points for drug discovery through high-content phenotypic profiling of esophageal adenocarcinoma cells.\n\n\n**16. Scaling laws for neural language models.**\n\n1. **Title:** Scaling laws for neural language models.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To investigate scaling laws in neural language models. The hypothesis is that performance in neural language modeling is predictable based on the scale of computation, data, and model parameters.\n\n4. **Summary of Results:** The research likely identified scaling laws that govern the performance of neural language models.\n\n\n**17. Evolutionary-scale prediction of atomic-level protein structure with a language model.**\n\n1. **Title:** Evolutionary-scale prediction of atomic-level protein structure with a language model.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To predict atomic-level protein structure using a language model trained on evolutionary data. The hypothesis is that language models can capture the underlying principles of protein structure and accurately predict their structures.\n\n4. **Summary of Results:**  The study likely demonstrated the ability of language models to predict atomic-level protein structure with high accuracy.\n\n\n**18. Superhuman cell death detection with biomarker-optimized neural networks.**\n\n1. **Title:** Superhuman cell death detection with biomarker-optimized neural networks.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To develop neural networks that can detect cell death with higher accuracy than humans. The hypothesis is that neural networks, particularly those optimized with biomarkers, can achieve superhuman performance in detecting cell death.\n\n4. **Summary of Results:** The research likely demonstrated the development of neural networks capable of surpassing human accuracy in cell death detection.\n\n\n**19. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.**\n\n1. **Title:** Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To review and compare experimental and computational methods for estimating drug solubility and permeability. The hypothesis is that a combination of experimental and computational approaches can provide more accurate and reliable estimates.\n\n4. **Summary of Results:** The review compares experimental and computational methods for predicting drug solubility and permeability, highlighting their strengths and limitations.\n\n\n**20. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity.**\n\n1. **Title:** Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To investigate the mechanism by which immunophilin-ligand complexes inhibit T cell signaling. The hypothesis is that this inhibition is correlated with a loss of calcineurin phosphatase activity.\n\n4. **Summary of Results:** The study demonstrated a correlation between the inhibition of T cell signaling by immunophilin-ligand complexes and a loss of calcineurin phosphatase activity.\n\n\n**21. Decoupled weight decay regularization.**\n\n1. **Title:** Decoupled weight decay regularization.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To propose a new method for weight decay regularization in neural networks. The hypothesis is that decoupling weight decay from the gradient update will improve the performance and stability of training.\n\n4. **Summary of Results:** The paper introduces a decoupled weight decay regularization method, likely demonstrating its benefits in neural network training.\n\n\n**22. De novo generation of hit-like molecules from gene expression signatures using artificial intelligence.**\n\n1. **Title:** De novo generation of hit-like molecules from gene expression signatures using artificial intelligence.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To generate novel drug-like molecules based on gene expression signatures using artificial intelligence. The hypothesis is that AI can be used to design molecules with desired biological effects based on gene expression data.\n\n4. **Summary of Results:** The study likely demonstrated the successful generation of novel drug-like molecules based on gene expression data using AI.\n\n\n**23. Predicting compound activity from phenotypic profiles and chemical structures.**\n\n1. **Title:** Predicting compound activity from phenotypic profiles and chemical structures.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To predict compound activity using both phenotypic profiles and chemical structures. The hypothesis is that combining these two data types will improve the accuracy of activity prediction.\n\n4. **Summary of Results:** The research likely demonstrated improved accuracy in predicting compound activity by integrating phenotypic profiles and chemical structures.\n\n\n**24. Molecular sets (MOSES): A benchmarking platform for molecular generation models.**\n\n1. **Title:** Molecular sets (MOSES): A benchmarking platform for molecular generation models.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To create a benchmarking platform (MOSES) for evaluating molecular generation models. The hypothesis is that a standardized benchmark is needed to objectively compare different molecular generation models.\n\n4. **Summary of Results:** The paper introduces MOSES, a benchmarking platform for evaluating molecular generation models, providing a standardized way to compare different models.\n\n\n**25. Fr\u00e9chet ChemNet distance: A metric for generative models for molecules in drug discovery.**\n\n1. **Title:** Fr\u00e9chet ChemNet distance: A metric for generative models for molecules in drug discovery.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To propose a new metric (Fr\u00e9chet ChemNet distance) for evaluating generative models for molecules in drug discovery. The hypothesis is that this metric will provide a more meaningful evaluation of the quality of generated molecules.\n\n4. **Summary of Results:** The paper introduces the Fr\u00e9chet ChemNet distance as a metric for evaluating molecular generative models.\n\n\n**26. Repurposing High-Throughput image assays enables biological activity prediction for drug discovery.**\n\n1. **Title:** Repurposing High-Throughput image assays enables biological activity prediction for drug discovery.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To repurpose high-throughput image assays for predicting biological activity in drug discovery. The hypothesis is that image-based data can be used to predict the biological activity of compounds.\n\n4. **Summary of Results:** The study likely demonstrated the successful repurposing of high-throughput image assays for predicting biological activity, improving drug discovery efficiency.\n\n\n**27. Deducing the mechanism of action of compounds identified in phenotypic screens by integrating their multiparametric profiles with a reference genetic screen.**\n\n1. **Title:** Deducing the mechanism of action of compounds identified in phenotypic screens by integrating their multiparametric profiles with a reference genetic screen.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To deduce the mechanism of action of compounds identified in phenotypic screens by integrating multiparametric profiles with a reference genetic screen. The hypothesis is that combining these data types will improve the ability to determine the mechanism of action.\n\n4. **Summary of Results:** The research likely demonstrated successful deduction of compound mechanisms of action by integrating multiparametric profiles with genetic screen data.\n\n\n**28. The bitter lesson.**\n\n1. **Title:** The bitter lesson.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:**  To argue that general methods that leverage computation are ultimately the most effective in AI. The hypothesis is that focusing on improving general methods and scaling up computation is more effective than pursuing narrow, specialized approaches.\n\n4. **Summary of Results:** The paper argues that general methods that leverage computation are superior to specialized approaches in AI.\n\n\n**29. Computer-aided drug design: the next 20 years.**\n\n1. **Title:** Computer-aided drug design: the next 20 years.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To predict the future of computer-aided drug design. The hypothesis is that computer-aided drug design will play an increasingly important role in drug discovery.\n\n4. **Summary of Results:** The paper predicts the future trends and advancements in computer-aided drug design.\n\n\n**30. Fluorescently labeled nuclear morphology is highly informative of neurotoxicity.**\n\n1. **Title:** Fluorescently labeled nuclear morphology is highly informative of neurotoxicity.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To investigate the relationship between fluorescently labeled nuclear morphology and neurotoxicity. The hypothesis is that changes in nuclear morphology can serve as an indicator of neurotoxicity.\n\n4. **Summary of Results:** The study likely demonstrated the utility of nuclear morphology as a biomarker for neurotoxicity.\n\n\n**31. Deep representation learning determines drug mechanism of action from cell painting images.**\n\n1. **Title:** Deep representation learning determines drug mechanism of action from cell painting images.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To determine drug mechanism of action from cell painting images using deep representation learning. The hypothesis is that deep learning models can accurately predict drug mechanisms of action from image data.\n\n4. **Summary of Results:** The research likely demonstrated successful prediction of drug mechanisms of action from cell painting images using deep learning.\n\n\n**32. MoleculeNet: A benchmark for molecular machine learning.**\n\n1. **Title:** MoleculeNet: A benchmark for molecular machine learning.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To create a benchmark dataset (MoleculeNet) for evaluating molecular machine learning models. The hypothesis is that a standardized benchmark is needed to objectively compare different molecular machine learning models.\n\n4. **Summary of Results:** The paper introduces MoleculeNet, a comprehensive benchmark dataset for evaluating molecular machine learning models, providing a standardized way to compare different models.\n\n\n**33. Integrating high-content screening and ligand-target prediction to identify mechanism of action.**\n\n1. **Title:** Integrating high-content screening and ligand-target prediction to identify mechanism of action.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To integrate high-content screening and ligand-target prediction to identify mechanisms of action. The hypothesis is that combining these approaches will lead to more accurate and efficient identification of mechanisms of action.\n\n4. **Summary of Results:** The study likely demonstrated improved identification of mechanisms of action by combining high-content screening and ligand-target prediction.\n\n\n**34. A simple and robust method for connecting small-molecule drugs using gene-expression signatures.**\n\n1. **Title:** A simple and robust method for connecting small-molecule drugs using gene-expression signatures.\n\n2. **Abstract:** Not provided in excerpt.\n\n3. **Main Idea and Hypothesis:** To develop a method for connecting small-molecule drugs based on their gene expression signatures. The hypothesis is that drugs with similar gene expression profiles have related mechanisms of action.\n\n4. **Summary of Results:** The paper presents a method for connecting small-molecule drugs based on their gene expression signatures.\n\n\n**35. VDDB: a comprehensive resource and machine learning platform for antiviral drug discovery.**\n\n1. **Title:** VDDB: a comprehensive resource and machine learning platform for antiviral drug discovery.\n\n2. **Abstract:** To present an open-access antiviral drug resource and machine learning platform (VDDB) to accelerate the design and discovery of new antiviral drugs.  The hypothesis is that a centralized, curated database with integrated machine learning models will accelerate antiviral drug discovery.\n\n3. **Main Idea and Hypothesis:**  To create a comprehensive database (VDDB) of antiviral drugs and integrate machine learning models to facilitate drug discovery.\n\n4. **Summary of Results:** The authors developed VDDB, a comprehensive database of antiviral drugs and molecules, including machine learning models for various drug discovery tasks such as compound activity prediction, virtual screening, and target fishing.\n\n\n**36. Lo-Hi: Practical ML Drug Discovery Benchmark**\n\n1. **Title:** Lo-Hi: Practical ML Drug Discovery Benchmark\n\n2. **Abstract:** Existing benchmarks for molecular property prediction are unrealistic and differ from practical applications.  This paper introduces a new practical Lo-Hi benchmark with Lead Optimization (Lo) and Hit Identification (Hi) tasks, mirroring the real drug discovery process.  The hypothesis is that a benchmark reflecting real-world scenarios will better evaluate machine learning models for drug discovery.\n\n3. **Main Idea and Hypothesis:** To create a more realistic benchmark for evaluating machine learning models in drug discovery by focusing on the Lead Optimization and Hit Identification stages.\n\n4. **Summary of Results:** The authors created the Lo-Hi benchmark, demonstrating that existing benchmarks are unrealistic. They evaluated various ML models, finding Chemprop best for Hit Identification and SVM for Lead Optimization, highlighting the task-specificity of model performance.  A novel molecular splitting algorithm was also developed to create more realistic datasets for the Hit Identification task.\n\n\n**37. Neural scaling laws for phenotypic drug discovery**\n\n1. **Title:** Neural scaling laws for phenotypic drug discovery\n\n2. **Abstract:** The authors investigate whether scaling up models and data in deep learning can similarly impact small molecule drug discovery. They use a benchmark (Pheno-CA) on image-based high-content screening data.  The hypothesis is that scaling up models and data will improve performance on drug discovery tasks, similar to other AI domains.\n\n3. **Main Idea and Hypothesis:** To determine if neural scaling laws apply to deep learning models for drug discovery using image-based high-content screening data.\n\n4. **Summary of Results:**  The authors found that task-supervised DNNs did not consistently improve with increased data and model size.  However, DNNs pretrained on a novel precursor task (Inverse Biological Process, IBP) significantly outperformed task-supervised DNNs and followed linear scaling laws.  This suggests that sufficient data and model size are key to improving performance, and projects the amount of data needed to reach 100% accuracy on certain tasks.\n\n\n**38. Comparison of Algorithms that Detect Drug Side Effects using Electronic Healthcare Databases**\n\n1. **Title:** Comparison of Algorithms that Detect Drug Side Effects using Electronic Healthcare Databases\n\n2. **Abstract:** The authors compare four algorithms (MUTARA, HUNT, Temporal Pattern Discovery, and modified ROR) for detecting adverse drug reactions (ADRs) using the THIN electronic healthcare database.  The hypothesis is that these algorithms will have different strengths and weaknesses in detecting ADRs from this type of data.\n\n3. **Main Idea and Hypothesis:** To compare the performance of several algorithms designed to detect adverse drug reactions (ADRs) using electronic health records (EHRs).\n\n4. **Summary of Results:** The study compared four algorithms on the THIN database, finding that no single algorithm was universally superior.  The algorithms' performance varied depending on the specific drug and the rarity of the ADR.  The study highlights the need for further algorithm development and the challenges of detecting rare ADRs.\n\n\nI hope these summaries are helpful!  Let me know if you need any clarifications or further analysis.",
        "sources": [
            "http://arxiv.org/abs/2309.16773v1",
            "http://arxiv.org/abs/1409.0748v1",
            "http://arxiv.org/abs/2209.13521v1",
            "http://arxiv.org/abs/2106.05386v4",
            "http://arxiv.org/abs/2310.06399v1",
            "http://arxiv.org/abs/2309.16773v1",
            "http://arxiv.org/abs/2106.05386v4",
            "http://arxiv.org/abs/2310.06399v1",
            "http://arxiv.org/abs/2310.06399v1",
            "http://arxiv.org/abs/2106.05386v4",
            "http://arxiv.org/abs/2106.05386v4",
            "http://arxiv.org/abs/2310.06399v1",
            "http://arxiv.org/abs/2309.16773v1",
            "http://arxiv.org/abs/2106.05386v4",
            "http://arxiv.org/abs/1409.0748v1"
        ]
    }
]